Nkarta, Inc. (NKTX)
1.81
+0.24
(+15.29%)
USD |
NASDAQ |
Nov 06, 11:36
Nkarta Enterprise Value : 3.222M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 3.222M |
| November 04, 2026 | 14.68M |
| November 03, 2026 | 0.357M |
| November 02, 2026 | -0.3593M |
| October 30, 2026 | 2.506M |
| October 29, 2026 | 9.668M |
| October 28, 2026 | 13.97M |
| October 27, 2026 | 12.53M |
| October 26, 2026 | 21.84M |
| October 23, 2026 | 18.98M |
| October 22, 2026 | 15.40M |
| October 21, 2026 | 16.11M |
| October 20, 2026 | 15.40M |
| October 19, 2026 | 16.11M |
| October 16, 2026 | 19.70M |
| October 15, 2026 | 29.01M |
| October 14, 2026 | 36.17M |
| October 13, 2026 | 41.18M |
| October 12, 2026 | 46.20M |
| October 09, 2026 | 51.92M |
| October 08, 2026 | 49.78M |
| October 07, 2026 | 53.36M |
| October 06, 2026 | 56.22M |
| October 05, 2026 | 71.98M |
| October 02, 2026 | 75.20M |
| Date | Value |
|---|---|
| October 01, 2026 | 74.13M |
| September 30, 2026 | 78.43M |
| September 29, 2026 | 78.43M |
| September 28, 2026 | 82.01M |
| September 25, 2026 | 87.74M |
| September 24, 2026 | 94.90M |
| September 23, 2026 | 88.45M |
| September 22, 2026 | 102.06M |
| September 21, 2026 | 97.05M |
| September 18, 2026 | 93.47M |
| September 17, 2026 | 92.03M |
| September 16, 2026 | 96.33M |
| September 15, 2026 | 97.05M |
| September 14, 2026 | 99.91M |
| September 11, 2026 | 99.20M |
| September 10, 2026 | 92.03M |
| September 09, 2026 | 99.20M |
| September 08, 2026 | 122.11M |
| September 04, 2026 | 99.91M |
| September 03, 2026 | 90.60M |
| September 02, 2026 | 88.81M |
| September 01, 2026 | 84.15M |
| August 31, 2026 | 84.87M |
| August 28, 2026 | 88.45M |
| August 27, 2026 | 87.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Heron Therapeutics, Inc. | 159.79M |
| Tonix Pharmaceuticals Holding Corp. | -97.72M |
| Karyopharm Therapeutics, Inc. | 192.45M |
| Minerva Neurosciences, Inc. | 105.00M |
| Corbus Pharmaceuticals Holdings, Inc. | -60.28M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.37M |
| Total Expenses (Quarterly) | 40.37M |
| EPS Diluted (Quarterly) | -0.5419 |
| Earnings Yield | -87.31% |
| Normalized Earnings Yield | -91.48 |